Haemonetics Co. (NYSE:HAE) SVP Jacqueline Scanlan sold 4,890 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $112.19, for a total value of $548,609.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Haemonetics stock traded down $0.29 during midday trading on Friday, reaching $108.71. 499,126 shares of the company’s stock traded hands, compared to its average volume of 570,017. The company has a quick ratio of 1.94, a current ratio of 2.84 and a debt-to-equity ratio of 0.49. The company has a market cap of $5.92 billion, a PE ratio of 58.13, a P/E/G ratio of 3.73 and a beta of 1.02. Haemonetics Co. has a 12 month low of $44.61 and a 12 month high of $117.56.
Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, August 7th. The medical instruments supplier reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.17. The company had revenue of $229.35 million during the quarter, compared to the consensus estimate of $219.52 million. Haemonetics had a return on equity of 15.00% and a net margin of 2.45%. On average, research analysts anticipate that Haemonetics Co. will post 2.28 earnings per share for the current year.
HAE has been the subject of several recent research reports. Zacks Investment Research upgraded Haemonetics from a “hold” rating to a “buy” rating and set a $105.00 price objective for the company in a research report on Tuesday, June 12th. Jefferies Financial Group boosted their price objective on Haemonetics from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, June 14th. Morgan Stanley boosted their price objective on Haemonetics from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Wednesday, August 8th. Barrington Research boosted their price objective on Haemonetics from $90.00 to $118.00 and gave the company an “outperform” rating in a research report on Thursday, August 9th. Finally, TheStreet downgraded Haemonetics from a “b” rating to a “c+” rating in a research report on Monday, August 20th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $99.83.
Institutional investors have recently made changes to their positions in the stock. Wagner Bowman Management Corp bought a new position in shares of Haemonetics during the second quarter valued at approximately $224,000. Arjuna Capital bought a new position in shares of Haemonetics during the second quarter valued at approximately $224,000. Granahan Investment Management Inc. MA bought a new position in Haemonetics in the second quarter worth $229,000. Alpine Woods Capital Investors LLC bought a new position in Haemonetics in the first quarter worth $236,000. Finally, Zeke Capital Advisors LLC bought a new position in Haemonetics in the second quarter worth $244,000. Institutional investors own 95.74% of the company’s stock.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Read More: Earnings Per Share
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.